Quantcast

Latest CD44 Stories

2014-07-25 08:25:15

Phase I studies start in 2015 NEW HAVEN, Conn., July 25, 2014 /PRNewswire/ -- Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd. (ASX; NRT: NASDAQ; NVGN), today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil(TM). CanTx and Novogen expect to file an Investigational New Drug (IND) application for Cantrixil early next year and to advance this compound...

2014-06-17 08:28:31

Companies expect to commence first-in-human studies of Trx-1 in ovarian cancer in 1H15 BOSTON, June 17, 2014 /PRNewswire/ -- Australian oncology drug development company Novogen Limited [ASX:NRT; NASDAQ:NVGN] and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity. Based on the...

2013-12-05 10:31:04

The retinoblastoma (Rb) protein plays a critical role in suppressing the multi-step process of cell migration through the bloodstream, lymphovascular invasion and the metastasis of an aggressive type of breast cancer to the lung, researchers at the University of Cincinnati (UC) Cancer Institute, the Cincinnati Cancer Center (CCC) and the UC Brain Tumor Center have found. The findings of Rb's role at multiple points in the disease process point to a potential new therapeutic target in...

2013-03-26 11:03:41

Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells. The findings, published in the online Early Edition of the Proceedings of the National Academy of Sciences on March 25, 2013 represent a potential new therapy for treating at least some patients with CLL, the most common type of blood cancer in the United States. CLL cells express high levels...

2012-05-16 11:20:03

Cell surface protein blows potent cells' cover; targeted drug works in preclinical tests Breast cancer stem cells wear a cell surface protein that is part nametag and part bull's eye, identifying them as potent tumor-generating cells and flagging their vulnerability to a drug, researchers at The University of Texas MD Anderson Cancer Center report online in Journal of Clinical Investigation. "We've discovered a single marker for breast cancer stem cells and also found that it's...

2011-06-29 06:59:24

(Ivanhoe Newswire) "“ Idiopathic pulmonary fibrosis (IPF) affects about 100,000 people in the U.S. each year and is fatal within three years of diagnosis. An invasive cell that leads to lung fibrosis may be stopped by cutting off its supply of sugar, according to this study. IPF has only one therapy in the U. S.: lung transplantation. Duke researchers have found a possible new treatment by identifying a cell surface receptor on the invasive cells called myofibroblasts and an enzyme that...

2011-06-01 23:01:18

Potential new drug target for hard-to-treat 'triple-negative' tumors Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that is highly resistant to current therapies. Kornelia Polyak, MD, PhD, a breast cancer geneticist at Dana-Farber, and colleagues found that a large proportion of cells within these tumors showed elevated...

2011-04-06 23:27:45

A newly discovered hybrid gene appears to play a direct role in some stomach cancers, according to an international team of scientists led by researchers at Duke-NUS Graduate Medical School Singapore. The hybrid gene is a fusion of two separate genes, and is one of the first described in gastric cancer, which is the most lethal malignancy worldwide after lung cancer. The disease kills an estimated 740,000 people a year, including nearly 11,000 annually in the United States. The gene discovery...

2011-01-17 12:34:14

UT MD Anderson preclinical research boosts case for new drug approach A small slice of RNA inhibits prostate cancer metastasis by suppressing a surface protein commonly found on prostate cancer stem cells. A research team led by scientists at The University of Texas MD Anderson Cancer Center reported today in an advance online publication at Nature Medicine. "Our findings are the first to profile a microRNA expression pattern in prostate cancer stem cells and also establish a strong rationale...

2010-07-25 19:00:00

SINGAPORE, July 25 /PRNewswire-Asia/ -- Scientists from Singapore, Australia and Hong Kong have found that gamma-tocotrienol is potent in killing prostate cancer stem cells. This small group of cells is responsible for the initiation of prostate cancer and is resistant to conventional chemotherapy drugs. It causes relapses in the cancer by producing new chemo-resistant cancer cells. Gamma-tocotrienol is a member of the Vitamin E family and is derived naturally from palm oil. This...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related